Posted on Leave a comment

China’s CRISPR Cancer Cure Test is ahead of America

CRISPR cancer test

welcome By: Elena Grace Flores
In the field of medical science, the competition between the Chinese and American are also getting tougher. America already approved the University of Pennsylvania team’s CRISPR trial on humans, but the Chinese team from the Sichuan University’s West China Hospital in Chengdu is now about to test the efficiency of modified cells for lung cancer treatment this August. Patients are chosen from those who underwent chemotherapy, radiation therapy and other treatments but still did not get better.

Engadget posted: The scientists plan to take T cells (a type of white blood cell) from patients and use the CRISPR-Cas9 technique to edit out the PD-1 gene. PD-1 regulates T cells’ immune response and prevents them from attacking healthy cells. The team will then multiply the modified samples in the lab before reintroducing them to the patients’ bloodstream, in hopes that they’ll target parts of the patient’s body affected with cancer. A biotechnology company will validate the cells before they’re reintroduced into the patient to make sure only PD-1 was edited out. But Timothy Chan, an immunotherapy researcher from the Memorial Sloan Kettering Cancer Center in New York City, still has reservations about the team’s plan. He told Nature that he’s worried the cells would activate an excessive immune response that could target perfectly healthy tissues.

It noted: Chan suggested taking T cells directly from a tumor, but the Chinese scientists said the patients’ lung cancer tumors aren’t easily accessible. As a precaution, the team will start things slow. They’ll begin with 10 people and will initially administer increasing dosages on just one patient in order to monitor the results closely and to look out for side effects. It’s worth noting that Chinese scientists were also the first to use CRISPR editing on human embryos to repair a gene that causes fatal blood disorder. Their approach only worked on half the embryos, though, so they ultimately had to scrap the study.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.